Vascular & Wound Care

Critical Limb Ischemia and chronic wounds:

Most common cause of non-healing wounds are peripheral arterial occlusive (PAD) and Diabetic Microangiopathy

Risk factors associated with the development of PAD include individuals aged 65 years and older, Nicotine use, Diabetes mellitus, hypertension, hypercholesterolemia, and family history of cardiovascular disease.

Open surgical techniques to remove the blockage (bypass) endovascular treatment (balloon angioplasty) is mainstay of revascularisation: While the mechanism of action has not been

Patients who have failed or who are no longer candidates for these therapies, 20% will die and 50–90% a leg amputation in 6 months.

Research focused on the use of autologous cell therapy has shown promise and has led to several clinical studies where concentrated autologous bone marrow cells have been used as an Angiogenic treatment in patients who are not candidates of open or endovascular procedure

How it is done

The mechanism of action is postulated is that the improvements shown in perfusion and concomitantly in quality of life and walking capacity result from the effect of bone marrow cells on the small collateral vessels. The expansion of these vessels is the most important physiological repair mechanism in peripheral artery disease

As a day care procedure 240 ml of Bone marrow OR 100 ml of fat is aspirated and processed for stem cells isolation. stem cells processed as per GMP are injected either into

What to expect

Ankle-brachial index was significantly improved at rest from 0.66 to 0.80, after stress from 0.64 to 0.76
90 % of patients reported amelioration of rest pain and pain free walking time by 24-week
Pain-free walking distance increased from average of 150 m to 550m
Angiography evidence of collateral vessel formation observed in 70 % of the patients
Only 5 % patients needed amputation.

The website contains no medical advice. All statements and opinions provided by the website are for educational and informational purposes. ||The treatment centres associated with Revita lifesciences provide surgical procedure only and are not involved in use or manufacture of any investigational drug ||Revita does not claim that any application or potential application, using autologous stem cells are approved by the FDA. We do not claim that these procedures work for any listed nor unlisted condition, intended or implied.||It’s important for potential patients to do their own research based on the options we present so that one can make an informed decision. Any decision to participate in experimental protocol is completely voluntary ||

A to z of clinical and application based stem cell science under one roof

VASCUALR & WOUND CARE

Vascular & Wound Care

Critical Limb Ischemia and chronic wounds:

How it is done

What to expect